Tenofovir Nephrotoxicity

Here's a taste of what TheBody.com has to offer on this topic:

Ask the Experts

Lipoatrophy or Nephrotoxicity?

I've been hiv + for about 2 years, and I'm on treatment for 3 months. I'm using the following combination: Tenofovir + Lamivudine + Efavirenz.Tenofovir is recognized for haven a lower risk of lipoatrophy, but, it can be toxic for the...

Response from Keith Henry, M.D.

University of Minnesota, School of Medicine

The risk for severe kidney damage from tenofovir appears low overall over the first 5+ years of use though risk is higher if other risk factors for kidney disease exist (ie hypertension or diabetes). The risk of lipoatrophy for tenofovir is modest... Read more »

Follow up: Dialysis nurse with eye splash incident

Hello again Doctor,My nephrologist called back today and said Viread/Tenofovir in Truvada is... Read more »

Response from David Wohl, M.D. »

Viread changes?

I heard that there have been changes to the patient information for Viread and that new information... Read more »

Response from Brian Conway, M.D. »

Go to Ask the Experts »

Articles

Tenofovir-Containing Regimens May Not Be the Best Option for Patients With Abnormal Baseline Renal Function

Since the development of tenofovir (TDF, Viread) began, decreases in renal function among HIV-infected patients taking tenofovir-containing regimens have been reported. This was somewhat expected due to the renal clearance and metabolic pathway of... Read more »

Approval of Complera: Emtricitabine/Rilpivirine/Tenofovir DF Fixed-Dose Combination

On August 10, 2011, FDA approved Complera TM , a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera TM is one tablet, containing... Read more »

Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva (Efavirenz) and Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate)

New York, NY and Foster City, CA -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of... Read more »

Stribild ("Quad") Recommended as Alternative First-Line HIV Treatment Regimen by U.S. Guidelines Panel

The newly approved four-in-one HIV drug Stribild (elvitegravir/cobicistat/FTC/tenofovir), also known as the "Quad," has gotten a tentative nod from the panel of experts that revises the official U.S. HIV treatment guidelines for adults and... Read more »

Tools

My Health Tracker

Assess Your Risk for HIV

Find Local HIV/AIDS Services

Resource Centers

Guides for People With HIV

View All of Our Guides >>

Related Topics

View More HIV/AIDS-Related Topics »

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.